Bcal Diagnostics Limited · ASX:BDX
Bcal Diagnostics — 18th Bioshares Biotech Summit 2024
21 slides from Bcal Diagnostics's conference presentation, Jul 11, 2024
Slide 1: ASX Announcement: BCAL Diagnostics Corporate Presentation
11 July 2024 ASX Announcement BCAL Diagnostics Corporate Presentation Attached please find a Corporate Presentation to given by Jayne Shaw, Executive Chair of BCAL Diagnostics, at the 18th Bioshares Biotech Summit at the Esplanade Hotel in Fremantle, Western Australia on the 13 July 2024. This annou
Slide 2: Driving a New Paradigm in Breast Cancer Diagnostics
BCAL DIAGNOSTICS LIMITED ASX: BDX Bioshares Biotech Summit DRIVING A NEW PARADIGM IN BREAST CANCER DIAGNOSTICS Jayne Shaw | JULY 2024 CORPORATE PRESENTATION
Slide 3: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation (Presentation) has been prepared by BCAL Diagnostics Ltd The forward-looking statements are based on information available to BCAL Not An Offer ABN 51 142 051 223 (BCAL or the Company). as at the date of this Presentation. Circumstances may change and
Slide 4: Company Metrics
COMPANY METRICS ASX Code BDX Share Price 08 July 2024 $0.145 Shares on Issue 314M Unlisted Options 4.5M Cash 30 June 20241 $6.5M Top 20 Shareholders 52% Pre 15 July 2024 General Meeting regarding Tranche 2 of capital raise. If all of Trance 2 is approved, cash increases by $4.3m and shares on issue
Slide 5: A Lipid Blood Test with Automated Analysis
A LIPID BLOOD TEST WITH AUTOMATED ANALYSIS ~$300 Proposed cost of test to the patient, following independent research and } ALEARNING LIPIDOMIC PLATFORM THAT INCORPORATES AI MACHINE AND LEVERAGES ROBUST SCIENTIFIC RESEARCH focus group BREASTEST® TRANSIT Logistics AT COLLECTION CENTRE AT TESTING LABO
Slide 6: Corporate Presentation
BCA Laiasnostes DR DAVID , SPEAKMAN SURGICAL ONCOLOGIST
Slide 7: BREASTEST Will Be Used as a Screening Tool
® BREASTEST WILL BE USED AS A SCREENING TOOL SCREENING DIAGNOSTICS Contrast enhanced BREASTEST® Mammography Ultrasound 3D Mammography MRI mammography ▪ Simple blood test ▪ Painful procedure ▪ Used for mass/lesion ▪ Painful procedure ▪ Painful procedure ▪ High sensitivity differentiation, no ▪ Solves
Slide 8: Regulatory Pathway to Commercialisation
REGULATORY PATHWAY TO COMMERCIALISATION SEPTEMBER 2024 DECEMBER 2024 Establish: NATA is responsible for accrediting “Medical Testing Laboratory” Laboratory ISO 15189 NATA laboratories that develop/manufacture In National Pathology Accreditation Advisory Council (NPAAC) accreditation BREASTEST® Vitro
Slide 9: Australian Launch
AUSTRALIAN LAUNCH Launch of BREASTEST® in Australia late 2024 & first revenues CORPORATE PRESENTATION 8
Slide 10: Australian Distribution Landscape
AUSTRALIAN DISTRIBUTION LANDSCAPE CORPORATE PRESENTATION 9
Slide 11: Comprehensive Education Program
COMPREHENSIVE EDUCATION PROGRAM Establish BREASTEST® as effective, best-in-class screening technology for breast cancer CORPORATE PRESENTATION 10
Slide 12: BCAL Is Working with Clinicians from Leading Centres Around the Globe
BCAL IS WORKING WITH CLINICIANS FROM LEADING CENTRES AROUND THE GLOBE ▪ Lakeview Private Hospital ▪ Royal North Shore Hospital ▪ Dudley Private Hospital ▪ BreastScreen RPAH ▪ Westmead Breast Cancer Institute A pilot study assessing the feasibility of using the BCAL test for early diagnosis of breast
Slide 13: Focus Market Segments
FOCUS MARKET SEGMENTS } FOUR INITIAL KEY TARGET SEGMENTS 1 } 2 } 3 } 4 Adjunct to current Dense breast tissue Those who are not screened Interval testing standard of care ~40% if women have dense of 1.5 million people who; Phase 1 of launch; extremely dense breast tissue; ▪ Self exclude to due a per
Slide 14: Commercial Pathway
COMMERCIAL PATHWAY A 3-year roadmap to saving lives underpinned by a reproducible lipidomic platform and a proprietary biobank of growing data 02 Scale Nationally 03 Globalise 01 Australian launch CORPORATE PRESENTATION 13
Slide 15: BCAL – Accelerating Towards Commercialisation of BREASTEST
BCAL – ACCELERATING TOWARDS COMMERCIALISATION OF BREASTEST® ▪ NATA accreditation scheduled for September 2024, a key part of the inhouse IVD regulatory pathway ▪ Commercial launch in Australia in late 2024 ® BREASTEST ▪ Commercial launch to initially leverage existing relationship with sample a bloo
Slide 16: Thank you
Thank you Jayne Shaw Shane Ryan Executive Chair Chief Executive Officer jshaw@bcaldiagnostics.com sryan@bcaldiagnostics.com DRIVING A NEW PARADIGM IN BREAST CANCER DIAGNOSTICS BCAL Diagnostics Limited ABN 51 142 051 223 Suite 506, Lvl 5, 50 Clarence Street Sydney NSW 2000 CORPORATE PRESENTATION 15 www
Slide 17: Appendix
APPENDIX CORPORATE PRESENTATION 16
Slide 18: Clinic Advisory Board
CLINIC ADVISORY BOARD } Eminent and influential Breast Clinicians form a National Key Opinion Leader & Clinical Excellence Forum to enhance trust, provide advice and inform the BCAL program Dr David Speakman Prof Bruce Mann Dr Corinne Ooi A/Prof. James French Prof. Elisabeth Elder A/Prof. Cindy Mak D
Slide 19: Highly Experienced Board and Management
HIGHLY EXPERIENCED BOARD AND MANAGEMENT Jayne Shaw Hon Ron Phillips AO Mark Burrows AO Jonathan Trollip Dr. John Hurrell PhD Dr David Darling Executive Chair Non-executive Director Independent Independent Independent Non-Executive Director Successful businesswoman, Health policy expert, previously N
Slide 20: BREASTEST Has a Strong and Growing Intellectual Property Estates
® BREASTEST HAS A STRONG AND GROWING INTELLECTUAL PROPERTY ESTATES Expected Title IP covered Jurisdiction Status Patent number Priority date expiry date Methods for detecting cancer* Use of plasma lipids as a diagnostic method to detect breast and lung cancer AU (AU1) Granted AU Pat. No. 2011270968
Slide 21: Financial Model and Assumptions
FINANCIAL MODEL AND ASSUMPTIONS A showcase for the Australian roll-out of BCAL's BREASTEST® highlighting cashflow in } CY2025 at commencement of modelling, with significant market penetration Market Size captured through a phased roll-out plan: 16,000 – 30,000 tests in yr 1, ramping on a yearly basis
BCAL Diagnostics — 18th Bioshares Biotech Summit 2024 on 6ix